These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 8847891

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S.
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [Abstract] [Full Text] [Related]

  • 3. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M, Letscher-Bru V, Herbrecht R.
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [Abstract] [Full Text] [Related]

  • 4. Lipid formulations of amphotericin B.
    Dix SP, Andriole VT.
    Curr Clin Top Infect Dis; 2000 Dec; 20():1-23. PubMed ID: 10943516
    [Abstract] [Full Text] [Related]

  • 5. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
    Groll AH, Müller FM, Piscitelli SC, Walsh TJ.
    Klin Padiatr; 1998 Dec; 210(4):264-73. PubMed ID: 9743964
    [Abstract] [Full Text] [Related]

  • 6. The current role of amphotericin B lipid complex in managing systemic fungal infections.
    Chu P, Sadullah S.
    Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP.
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?
    Cifani C, Costantino S, Massi M, Berrino L.
    Acta Biomed; 2012 Aug; 83(2):154-63. PubMed ID: 23393924
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
    Patterson TF, Andriole VT.
    Eur J Cancer Clin Oncol; 1989 Aug; 25 Suppl 2():S63-8. PubMed ID: 2693111
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
    Hooshmand-Rad R, Reed MD, Chu A, Gotz V, Morris JA, Weinberg J, Dominguez EA.
    Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.